MARKET

PSTV

PSTV

Plus Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.5103
-0.0298
-5.52%
After Hours: 0.5267 +0.0164 +3.21% 16:53 07/05 EDT
OPEN
0.5323
PREV CLOSE
0.5401
HIGH
0.5323
LOW
0.5075
VOLUME
50.41K
TURNOVER
0
52 WEEK HIGH
2.600
52 WEEK LOW
0.4102
MARKET CAP
11.33M
P/E (TTM)
-0.5162
1D
5D
1M
3M
1Y
5Y
Plus Therapeutics inks contract to use Biocept's test for use in cancer trial
Plus Therapeutics (NASDAQ:PSTV) signed a multi-year agreement to use Biocept's (NASDAQ:BIOC) cerebrospinal fluid (CSF) assay CNSide in its phase 1/2a trial called ReSPECT-LM of Rhenium-186 NanoLiposome (186RNL) to treat patients with leptomeningeal metasta...
Seekingalpha · 06/22 13:00
BRIEF-Plus Therapeutics, Biocept Announce Comprehensive Laboratory Services Deal For Respect-LM Trial
BRIEF-Plus Therapeutics, Biocept Announce Comprehensive Laboratory Services Deal For Respect-LM Trial
Reuters · 06/22 11:55
Plus Therapeutics And Biocept Announce Laboratory Services Agreement For ReSPECT-LM Trial
Biocept’s CNSide™ assay provides a highly sensitive method to assess and quantify tumor cell burden in leptomeningeal metastasis (LM) of the central nervous system Assay results will be used to evaluate
Benzinga · 06/22 11:31
Plus Therapeutics and Biocept Announce Comprehensive Laboratory Services Agreement for the ReSPECT-LM Trial
Biocept’s CNSide™ assay provides a highly sensitive method to assess and quantify tumor cell burden in leptomeningeal metastasis (LM) of the central nervous system Assay results will be used to evaluate response to treatment and treatment efficacy for pati...
GlobeNewswire · 06/22 11:30
Plus Therapeutics Concludes Enrolment In Initial-Stage Study Of Cerebrospinal Fluid Cancer Setting
Plus Therapeutics (NASDAQ: PSTV) has concluded patient enrolment in the first cohort of the ReSPECT-LM Phase 1/2a dose escalation clinical trial of Rhenium-186 NanoLiposome (186RNL) for the treatment of leptomeningeal metastases (LM).
Benzinga · 06/16 15:36
Plus Therapeutics Says First Cohort Enrollment Complete in Trial of Investigational Cancer Treatment
MT Newswires · 06/16 10:24
BRIEF-Plus Therapeutics Reports Positive Clinical Outcomes From ReSPECT-GBM Trial At SNMMI 2022 Annual Meeting
reuters.com · 06/13 11:40
Plus Therapeutics Reports Clinical Outcomes From ReSPECT-GBM Trial At The Society Of Nuclear Medicine And Molecular Imaging 2022 Annual Meeting
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced
Benzinga · 06/13 11:07
More
No Data
Learn about the latest financial forecast of PSTV. Analyze the recent business situations of Plus Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PSTV stock price target is 4.833 with a high estimate of 7.00 and a low estimate of 2.000.
High7.00
Average4.833
Low2.000
Current 0.5103
EPS
Actual
Estimate
-0.22-0.17-0.11-0.06
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 36
Institutional Holdings: 3.26M
% Owned: 14.69%
Shares Outstanding: 22.20M
TypeInstitutionsShares
Increased
6
287.88K
New
3
1.61M
Decreased
4
346.21K
Sold Out
4
221.27K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.07%
Pharmaceuticals & Medical Research
+0.40%
Key Executives
Non-Executive Chairman/Independent Director
Richard Hawkins
President/Chief Executive Officer/Director
Marc Hedrick
Chief Financial Officer
Andrew Sims
Other
Norman LaFrance
Independent Director
Howard Clowes
Independent Director
Robert Lenk
Independent Director
Greg Petersen
Independent Director
Annigje Van Es-johansson
No Data
No Data
About PSTV
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing treatments for patients battling cancer. The Company provides nanotechnology platform to reformulate and improve workhorse chemotherapeutics to provide benefits to patients and healthcare providers. The Company is focused on developing generic oncology drugs that address unmet medical and market needs. The Company’s lead product candidate, DocePLUS, is an albumin-stabilized PEGylated liposomal formulation of docetaxel. DocePLUS is developed for the treatment of patients with small cell lung cancer (SCLC). The Company is also developing DoxoPLUS, which is a generic PEGylated liposomal formulation of doxorubicin. DoxoPLUS is developed for the treatment of breast cancer, ovarian cancer, multiple myeloma and Kaposi’s sarcoma. The Company also focuses on developing Rhenium-186 NanoLiposome (186RNL) for the treatment of recurrent glioblastoma-a rare, incurable and fatal disease.

Webull offers kinds of Plus Therapeutics Inc stock information, including NASDAQ:PSTV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PSTV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PSTV stock methods without spending real money on the virtual paper trading platform.